Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France

OBJECTIVE: To assess the cost-effectiveness of the elbasvir/grazoprevir (EBR/GZR) regimen in patients with genotype 1 chronic hepatitis C virus (HCV) infection with severe and end-stage renal disease compared to no treatment. DESIGN: This study uses a health economic model to estimate the cost-effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Maunoury, Franck, Clément, Aurore, Nwankwo, Chizoba, Levy-Bachelot, Laurie, Abergel, Armand, Di Martino, Vincent, Thervet, Eric, Durand-Zaleski, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854359/
https://www.ncbi.nlm.nih.gov/pubmed/29543897
http://dx.doi.org/10.1371/journal.pone.0194329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854359/
https://www.ncbi.nlm.nih.gov/pubmed/29543897
http://dx.doi.org/10.1371/journal.pone.0194329

Ejemplares similares